The effect of a unique propolis compound (propoelix™) on clinical outcomes in patients with dengue hemorrhagic fever

Infection and Drug Resistance

Volumn 7, Issue , 2014, Pages 323-329

  Soroy, Lardo ^a   Bagus, Sulistyo ^b   Yongkie, Iswandi Purnama ^a   Djoko, Wibisono ^b  

^a Division of Tropical Medicine and Infectious Disease Department of Internal Medicine   (Indonesia)

^b Gatot Soebroto Hospital   (Indonesia)

Author keywords

DHF; Effectiveness; Propoelix

Indexed keywords

PLACEBO; PROPOLIS; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DENGUE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HOSPITALIZATION; HUMAN; INDONESIA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT;

EID: 84917744252     PISSN: 11786973     EISSN: 11786973     Source Type: Journal    
DOI: 10.2147/IDR.S71505     Document Type: Article

References (13)

1. World Health Organization. Comprehensive Guidelines for Prevention and Control of Dengue and Dengue Haemorrhagic Fever: Revised and Expanded Edition. WHO Regional Offce for South East Asia; 2010. Available from: http://www.searo.who.int/entity/vector_borne_tropical_diseases/documents/SEAROTPS60/en/. Accessed November 11, 2014.
2. Birnbaumer DM. Fever in the returning traveler. In: Slaven EM, Stone SC, Lopez FA, editors. Infectious Diseases Emergency Department Diagnosis and Management. New York, NY: McGraw-Hill; 2007:418–427.
3. Nathan MB, Drager RD, Guzman M. Epidemiology, burden of disease and transmission. In: Dengue Guidelines for Diagnosis, Treatment, Prevention and Control. New Edition. Geneva, Switzearland: World Health Organization; 2009:3–17.
4. Suharti C. Pathogenesis of dengue hemorrhagic fever and dengue shock syndrome. In: Dengue Hemorraghic Fever in Indonesia: The Role of Cytokines in Plasma Leakage, Coagulation and Fibrinolysis. Nijmegen University Press; 2001:15–23.
5. Villar LA, Centeno, Quijano FAD, Vega RAM. Biochemical alterations as markers of dengue hemorrhagic fever. Am J Trop Med Hyg. 2008;78(3):370–374.
6. Fenglin CF, Chiu SC, Hsiao YL, et al. Expression of cytokine, chemokine, and adhesion molecules endothelial cell activation induced by antibodies against dengue virus nonstructural protein. J Immunol. 2005;174:395–403.
7. Fenglin CF, Lei HY, Shiau AL, et al. Endothelial cell apoptosis induced by antibodies against dengue virus nonstructural protein 1 via production of nitric oxide. J Immunol. 2002;169:657–664.
8. Fenglin CF, Lei HY, Shiau AL, Liu HS, Yeh TM. Patient and mouse antibodies against dengue virus nonstructural protein 1 cross-react with platelet and cause their dysfunction or depletion. Am J Infect Dis. 2008;169(2):657–664.
9. Lei HY, Huang KJ, Lin YS, Yeh TM, Liu HS. Immunopathogenesis of dengue haemorrhagic fever. Am J Infect Dis. 2008;4(1):1–9.
10. Lotfy M. Biological activity of bee propolis in health and disease. Asian Pac J Cancer Prev. 2006;7:22–31.
11. Borelli F, Maffa P, Pinto L, et al. Phytochemical compounds involved in the anti-inflammatory effect of propolis extract. Fitoterapia. 2002; 73 Suppl 1:S53–S63.
12. Marquez N, Sancho R, Macho A, Calzado MA, Fiebich BL, Munoz E. Caffeicacid phenethyl ester inhibits T-cell activation by targeting both nuclear factor activated T-cell and NF-kB transcription factors. J Pharmacol Exp Ther. 2004;308:993–1001.
13. Chakravarti A, Kumaria R. Circulating levels of tumour necrosis factor-α and interferon-γ in patients with dengue and dengue haemorrhagic fever during an outbreak. Indian J Med Res. 2006; 123:25–30.